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Abstract
The antitumour activities of four triorganophosphinegold(I) thiolates, R.PAu(S’R) [R Ph,
Cy, Et; SR’H 6-mercaptopurine and R Et; SR’H 6-thioguanine] against t5e National Cancer
Institute (NCI) panel of 60 cell lines are reported. The [CY3PAu(6-MP)] complex proved to be the
more cytotoxic of the four complexes tested. For the 6-MP series, an order of cytotoxicity was
established such that the activity followed the order R Cy > Ph > Et. Sub-panel selectivity against
the Leukemia cell lines was found for each of [CY3PAu(6-MP)] and [Et3PAu(6-TG)].
1. Introduction
The use of polymeric gold(I) thiolates such as sodium aurothiomalate (Myocrisin) and
aurothioglucose (Solganol)in the treatment of rheumatoid arthritis is well documented [1-3]. A
monomeric, orally administered species, [(1-thio--D-glucopyranose-2,3,4,6-tetraacetato-
S)(triethylphosphine)gold(I) (Auranofin), is also used clinically in this context. Spurred by the great
potential of heavy-metal complexes in the treatment of cancer, e.g. cisplatin, it was not surprising
that gold(I) complexes such as Auranofin [4] and other phosphinegold(I) thiolates [5,6] were
screened for their cytotoxicity. In Adelaide, a series of phosphinegold(I) thiolates, where the thiol is
derived from a thio-analogue of a nucleobase or closely related species, have been characterised
and both their anti-arthritic activity (in vivo) [7-9] and cytotoxicity (in vitro and in vivo) [10-13]
examined. Phosphinegold(I) complexes containing thiolates derived from 6-mercaptopurine (1)
and 6-thio-guanine (2) were generally found to be the most effective in ameliorating the
manifestations of induced autoallergic polyarthritis in dark Agouti rats, a gold-sensitive rat strain [14].
Comparisons, i.e. activity and toxicity, with the clinically used Myocrisin and Auranofin were
favourable, in this model [8,9]. The cytotoxicity of these and related species have also been
investigated in vitro and in one case preliminary in vivo results were obtained [13].
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These studies were encouraging and hence, l a-c and 2 were submitted for evaluation to the
National Cancer Institute against their panel of cell lines. The results of these screens are
presented herein.
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2. Experimental
2. 1 Synthesis
The complexes were prepared as reported previously [8].
2.2. Antitumour screening
The in vitro antitumour screening were performed at the Department of Health & Human
Services, National Institues of Health, National Cancer Institute, Bethesda, Maryland 20892, USA.
A panel of 60 human tumour lines derived from the following nine cancer types: Leukemia, Non-
Small Cell Lung Cancer, Colon Cancer, Central Nervous System (CNS) Cancer, Melanoma, Ovarian
Cancer, Renal Cancer, Prostate Cancer and Breast Cancer, was employed using the established
protocol [15]. The cells lines investigated are
Leukemia: CCRF-CEM, HL-60 (TB), K-562, MOLT-4, RPMI-8226, and SR;
Non-Small Cell Lung Cancer: A549/ATCC, HOP-62, HOP-92, NCI-H226, NCI-H23,
NCI-H322M, and NCI-H522;
Colon Cancer: COLO 205, HCT-116, HCT-15, HT29, KM12, and SW-620;
Central Nervous System Cancer: SF-268, SF-295, SF-539; SNB-19, SNB-75, and
U251;
Melanoma: LOX IMVl, MALME-3M, M14, SK-MEL-2, SK-MEL-28, SK-MEL-5, UACC-257,
and UACC-62;
Ovarian Cancer: IGROVl, OVCAR-3, OVCAR-4, OVCAR-5, OVCAR-8, and SK-OV-3;
Renal Cancer: 786-0, A498, ACHN, CAKI-1, RXF 393, SN12C, TK-10, and UO-31;
Prostate Cancer: PC-3 and DU-145;
Breast Cancer: MCF7, MCF7/ADR-RES, MDA-MB-231/ATCC, HS 578T, MDA-MB-435,
MDA-N, BT-549, and T-47D.
3. Assays
3.1 Mean response concentrations
The effect of administration of the complexes la-c and 2 on the health of the cell lines is
represented by the number of viable cells remaining after treatment. This number may be
moderated by i) a decrease in cell growth and proliferation, and ii) cell death. Three response
parameters are presented to indicate the response of the cells to the gold complexes. These are i)
GI5o, the concentration of gold complex that yields 50 % Growth Inhibition of the cells (i.e.
percentage growth +50); ii) TGI, the concentration that causes Total Growth Inhibition (i.e.
percentage growth 0); and iii) LCso, the concentration of gold complex at which only 50 % of the
cells are viable (i.e. percentage growth -50). The results of the screening were analysed at the
NCl using the program COMPARE [16]. The graphical results (logarithmic scale) are presented in
Figures -4 for l a-c and 2, respectively. The graphs show the relative sensitivities of the cell
lines, derived from the GI5o, TGI and LCso results, to the gold complexes. The bars projecting to the
right represent an increase in the sensitivity of the cell line to the gold complex compared with the
average sensitivity. Conversely, bars projecting to the left represent a decrease in sensitivity. The
mean response concentrations for each of the gold complexes are collected in Table 1.
Table 1. Mean response concentrations (M) for the four phosphinegold(I) thiolates
screened against the NCI panel of cell lines
Mean response
parameter
[Ph3PAu(6-MP)] [Cy3PAu(6-MP)] [Et3PAu(6-MP)] [Et3PAu(6-TG)]
Glo 1.70e-06 1.38e-06 1.82e-06 1.70e-06
TGI 4.90e-06 4.17e-06 6.46e-06 7.94e-06
LCso 1.41 e-05 1.38e-05 2.14e-05 2.57e-05
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Figure 1. Mean graph representation of the differential data for [Ph PAu(6-MP)].
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Figure 2. Mean graph representation of the differential data for [CyaPAu(6-MP)],.i i
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Figure 3. Mean graph representation of the differential data for [Et3PAu(6-MP)].
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Figure 4. Mean graph representation of the differential data for [Et3PAu(6-TG)].
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3.2 Differential cellular sensitivities
The differential cellular sensitivities for the phosphinegold(I) thiolates are listed in Table 2.
The differential sensitivity (z)is the mean cytotoxic potency of a particular compound
A Iogo(1/X) mean[Iogo(1/X)]; X Glo, TGI or LCo
computed over the complete panel of cell lines. Values of lower than represent low sensitivity,
values between and 3 indicate moderate sensitivity and those over 3 indicate high sensitivity.
Table 2. The differential cellular sensitivities (z) for the four phosphinegold(I) thiolates
screened against the NCI panel of cell lines
Differential cellular
sensitivity
[Ph3PAu(6-MP)] [CysPAu(6-MP)] [EtPAu(6-MP)] [Et3PAu(6-TG)]
Glo 1.8 1.5 2.0 2.2
TGI 1.4 2.4 1.6 1.9
LCo 1.4 1.4 1.4 1.4
4. Results and discussion
An examination of the mean graph data illustrated in Figure shows that the [PhaPAu(6-
MP)] complex displays no sub-panel selectivity. Maximum cytotoxicity was found against the
Leukemia cell lines K-562 and RPMI-8226 as well as the Melanoma cell line LOX IMVI. By contrast,
[CyPAu(6-MP)] displays sub-panel selectivity, being cytotoxic to the cell lines comprising the
Leukemia sub-panel. Maximum cytotoxicity was against the Leukemia line HL-60(TB) with
approximately one tenth of the average concentration of the complex was required to achieve the
average Glo, TGI and LCo values for this particular cell line. For [EtPAu(6-MP)], with the exception
of the the Leukemia cell line HL-60(TB), sub-panel sensitivity was found for the Leukemia sub-
panel. Greatest activity was found against HS 578T (Breast Cancer) and NCI-H522 (Non-Small Cell
Lung Cancer), each of which display a higher than average response, requiring about one tenth of
the concentration to effect the same average responses in Glo, TGI and LCo. As with [Cy3PAu(6-
MP)], [EtPAu(6-TG)] displays sub-panel selectivity against the Leukemia cell lines. [EtPAu(6-TG)]
also displays maximum activity in this cell line with the SR cell line being the most sensitive.
The four phosphinegold(I) thiolates exhibited moderate responses to all the differential
cellular sensitivity parameters as, uniformly, the values for z were less than 3; see in Table 2. The
Glo, TGI parameters indicate that these complexes inhibited cellular growth at a moderate rate, and,
from the LCo values, at best, are moderately cytotoxic.
Of the four phosphinegold(I) thiolate complexes evaluated by the NCI, [Cy3PAu(6-MP)]
displayed the greatest cytotoxicity having displayed the lowest average Glo, TGI and LCo values.
Using this criterion, an order of cytotoxicity may be constructed for the three 6-mercaptopurinate
complexes, i.e. R Cy > Ph > Et. The [CyPAu(6-MP)], [Et3PAu(6-TG)], and to a lesser extent
[EtPAu(6-MP)], complexes display sub-panel selectivity against the Leukemia cell lines. It is noted
that both of the thiopurines, 6-mercaptopurine and 6-thioguanine, have been used in the
treatment of Leukemia [17,18] and hence, the activity of their phosphinegold(I) complexes against
this cell line is, perhaps, not that surprising. It is also worth noting that previous studies have shown
that the presence of the phosphinegold(I) entity imparts greater cytotoxicity Compared with the
individual thiopurines [11].
Although both of the [Et3PAu(6-MP)] and [EtPAu(6-TG)] complexes were subjected to
repeat screening and subsequently referred to the Biological Evaluation Committee of the NCI, no
further action was recommended.
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